CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • ENTA Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Enanta Pharmaceuticals (ENTA)

Company Profile
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.
Enanta Pharmaceuticals logo

Company profile

Ticker
ENTA
Exchange
NASDAQ
Website
www.enanta.com
CEO
Jay Luly
Employees
Incorporated
Delaware
Location
Massachusetts
Fiscal year end
Sep 30
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
SEC CIK
0001177648
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
Enanta Pharmaceuticals Security Corporation ...

ENTA stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$53.00
Low target
$49.00
High target
$56.00
SVB Leerink
Maintains
Market Perform
$49.00
27 Jan 23
HC Wainwright & Co.
Initiated
Buy
$56.00
9 Dec 22
RBC Capital
Maintains
Sector Perform
$54.00
22 Nov 22
Latest filings (excl ownership)
View all
DEFA14A
Additional proxy soliciting materials
20 Jan 23
DEF 14A
Definitive proxy
20 Jan 23
10-K
2022 FY
Annual report
23 Nov 22
8-K
Results of Operations and Financial Condition
21 Nov 22
8-K
Entry into a Material Definitive Agreement
26 Aug 22
424B5
Prospectus supplement for primary offering
26 Aug 22
10-Q
2022 Q3
Quarterly report
8 Aug 22
8-K
Results of Operations and Financial Condition
8 Aug 22
8-K
Other Events
22 Jun 22
8-K
Entry into a Material Definitive Agreement
17 May 22
Transcripts
View all
ENTA
Earnings call transcript
2022 Q4
21 Nov 22
ENTA
Earnings call transcript
2022 Q3
9 Aug 22
ENTA
Earnings call transcript
2022 Q2
10 May 22
ENTA
Earnings call transcript
2022 Q1
9 Feb 22
ENTA
Earnings call transcript
2021 Q4
23 Nov 21
ENTA
Earnings call transcript
2021 Q3
8 Aug 21
ENTA
Earnings call transcript
2021 Q2
10 May 21
ENTA
Earnings call transcript
2021 Q1
9 Feb 21
ENTA
Earnings call transcript
2020 Q4
23 Nov 20
ENTA
Earnings call transcript
2020 Q3
5 Aug 20
Latest ownership filings
View all
4
PAUL J MELLETT
10 Jan 23
4
PAUL J MELLETT
19 Dec 22
4
Jay R. Luly
19 Dec 22
4
Jay R. Luly
16 Dec 22
4
Brendan Luu
5 Dec 22
4
Tara Lynn Kieffer
5 Dec 22
4
Nathaniel S. Gardiner
5 Dec 22
4
Yat Sun Or
5 Dec 22
4
PAUL J MELLETT
5 Dec 22
4
Jay R. Luly
5 Dec 22

Financial summary

Financial statements Chart ENTA financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Sep 22 Sep 21 Sep 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 43.99 mm 43.99 mm 43.99 mm 43.99 mm 43.99 mm 43.99 mm
Cash burn (monthly) (no burn) 1.10 mm 9.02 mm 10.32 mm 5.18 mm 7.07 mm
Cash used (since last report) n/a 4.44 mm 36.34 mm 41.60 mm 20.87 mm 28.48 mm
Cash remaining n/a 39.56 mm 7.65 mm 2.39 mm 23.12 mm 15.51 mm
Runway (months of cash) n/a 35.9 0.8 0.2 4.5 2.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

ENTA institutional ownership history Ownership history
86.5% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 155 152 +2.0%
Opened positions 20 11 +81.8%
Closed positions 17 23 -26.1%
Increased positions 62 55 +12.7%
Reduced positions 46 57 -19.3%
13F shares Current Prev Q Change
Total value 936.83 mm 943.94 mm -0.8%
Total shares 18.06 mm 19.97 mm -9.5%
Total puts 21.90 k 12.10 k +81.0%
Total calls 189.60 k 117.60 k +61.2%
Total put/call ratio 0.1 0.1 +12.3%
Largest owners Shares Value Change
BLK Blackrock 3.62 mm $187.86 mm +2.9%
Armistice Capital 2.07 mm $107.48 mm +0.1%
Farallon Capital Management 1.55 mm $80.40 mm 0.0%
Vanguard 1.48 mm $76.61 mm -2.6%
NTRS Northern Trust 964.41 k $50.02 mm +3.6%
Ra Capital Management 896.72 k $46.51 mm 0.0%
Krensavage Asset Management 589.36 k $30.57 mm -5.7%
Dimensional Fund Advisors 509.88 k $26.45 mm -2.6%
Fairmount Funds Management 469.26 k $24.34 mm 0.0%
Renaissance Technologies 468.00 k $24.28 mm -13.8%
Largest transactions Shares Bought/sold Change
STT State Street 0.00 -1.70 mm EXIT
Paradigm Biocapital Advisors 0.00 -148.22 k EXIT
IVZ Invesco 356.18 k -143.35 k -28.7%
Assenagon Asset Management 23.06 k -114.21 k -83.2%
Commodore Capital 103.49 k +103.49 k NEW
BLK Blackrock 3.62 mm +103.06 k +2.9%
Alliancebernstein 51.03 k -75.18 k -59.6%
Renaissance Technologies 468.00 k -74.80 k -13.8%
MS Morgan Stanley 181.67 k -63.20 k -25.8%
BMO Bank of Montreal 0.00 -58.92 k EXIT
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ENTA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Jan 23 Mellett Paul J Common Stock Option exercise Acquire M No No 14.18 2,812 39.87 k 88,463
9 Jan 23 Mellett Paul J Stock Option Common Stock Option exercise Dispose M No No 14.18 2,812 39.87 k 0
19 Dec 22 Luly Jay R. Common Stock Option exercise Acquire M No No 27.58 14,500 399.91 k 788,305
19 Dec 22 Luly Jay R. Stock Option Common Stock Option exercise Dispose M No No 27.58 14,500 399.91 k 55,500
19 Dec 22 Mellett Paul J Common Stock Option exercise Acquire M No No 14.18 4,148 58.82 k 85,651
19 Dec 22 Mellett Paul J Stock Option Common Stock Option exercise Dispose M No No 14.18 4,148 58.82 k 0
16 Dec 22 Luly Jay R. Common Stock Sell Dispose S No Yes 45.49 13,603 618.80 k 773,805
16 Dec 22 Luly Jay R. Common Stock Sell Dispose S No Yes 44.54 8,597 382.91 k 787,408
16 Dec 22 Luly Jay R. Common Stock Sell Dispose S No Yes 43.59 7,800 340.00 k 796,005
16 Dec 22 Luly Jay R. Common Stock Option exercise Acquire M No No 14 13,851 193.91 k 803,805
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
SVB Leerink Maintains Market Perform on Enanta Pharma, Lowers Price Target to $49
27 Jan 23
SVB Leerink analyst Roanna Ruiz maintains Enanta Pharma (NASDAQ:ENTA) with a Market Perform and lowers the price target from $50 to $49.
HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56
9 Dec 22
HC Wainwright & Co. analyst Ed Arce initiates coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with a Buy rating and announces Price Target of $56.
RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54
22 Nov 22
RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and lowers the price target from $65 to $54.
Enanta Pharmaceuticals Q4 EPS $(1.27) Beats $(1.35) Estimate, Sales $20.32M Miss $22.86M Estimate
21 Nov 22
Earnings Scheduled For November 21, 2022
21 Nov 22

Press releases

From Benzinga Pro
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
6 Jan 23
Progresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023 Presents New Preclinical In Vivo Data Demonstrating EDP-235's Efficacy and Prevention of
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
22 Nov 22
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
21 Nov 22
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
9 Nov 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn